Nammi Therapeutics Inc
Nammi Therapeutics is an immunotherapy company focused on developing first-in-class products for cancer treatment. Their approach emphasizes immune activation at the tumor site, avoiding systemic side effects, and employing mechanisms for targeted delivery and activation within tumors. They aim to extend the benefits of immunotherapy to all cancer patients by addressing key challenges such as immune pathway redundancy, systemic toxicities, and high costs of clinical development.
Industries
Nr. of Employees
small (1-50)
Nammi Therapeutics Inc
Patents
Formulated and/or co-formulated liposome compositions containing toll-like receptor(“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof
US-12311010-B2
View DetailsFormulated and/or co-formulated liposome compositions containing IDO antagonist prodrugs useful in the treatment of cancer and methods thereof
US-12286403-B2
View DetailsFusion protein composition(s) comprising masked type i interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereof
US-12162958-B2
View DetailsFormulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof
US-12059470-B2
View DetailsFormulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof
US-11896646-B2
View DetailsFormulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof
US-11833209-B2
View Details
Formulated and/or co-formulated liposome compositions containing toll-like receptor(“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof
US-12311010-B2
View DetailsFormulated and/or co-formulated liposome compositions containing IDO antagonist prodrugs useful in the treatment of cancer and methods thereof
US-12286403-B2
View DetailsFusion protein composition(s) comprising masked type i interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereof
US-12162958-B2
View DetailsFormulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof
US-12059470-B2
View DetailsFormulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof
US-11896646-B2
View DetailsFormulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof
US-11833209-B2
View DetailsProducts
QXL138AM
Tumor‑antigen‑targeted masked immunocytokine consisting of an interferon-alpha fused to an antibody targeting CD138 with a protease‑cleavable peptide mask to limit systemic activation.
SLNP‑IC1
Solid lipid nanoparticle formulation incorporating a doxorubicin prodrug designed to improve drug stability, reduce premature release, and enhance therapeutic window relative to liposomal doxorubicin.
NTI‑121
Solid lipid nanoparticle co‑formulation containing a doxorubicin prodrug and a toll‑like receptor 7 agonist prodrug intended to combine cytotoxic and innate immune stimulation within tumors.
QXL138AM
Tumor‑antigen‑targeted masked immunocytokine consisting of an interferon-alpha fused to an antibody targeting CD138 with a protease‑cleavable peptide mask to limit systemic activation.
SLNP‑IC1
Solid lipid nanoparticle formulation incorporating a doxorubicin prodrug designed to improve drug stability, reduce premature release, and enhance therapeutic window relative to liposomal doxorubicin.
NTI‑121
Solid lipid nanoparticle co‑formulation containing a doxorubicin prodrug and a toll‑like receptor 7 agonist prodrug intended to combine cytotoxic and innate immune stimulation within tumors.
Services
Manufacture and analytical activities to support regulatory submissions for first‑in‑human oncology studies.
Formulation of nanoparticle‑based prodrugs and execution of murine tumor model studies to evaluate stability, potency, and tumor growth inhibition.
Operational capability to initiate and run first‑in‑human Phase I oncology trials, including initial patient dosing.
Manufacture and analytical activities to support regulatory submissions for first‑in‑human oncology studies.
Formulation of nanoparticle‑based prodrugs and execution of murine tumor model studies to evaluate stability, potency, and tumor growth inhibition.
Operational capability to initiate and run first‑in‑human Phase I oncology trials, including initial patient dosing.
Expertise Areas
- Immuno-oncology therapeutic development
- Targeted biologic engineering (antibody–cytokine fusions)
- Nanomedicine and lipid nanoparticle formulation
- Prodrug chemistry and intracellular activation strategies
Key Technologies
- Antibody–cytokine fusion proteins
- Protease-cleavable peptide masks/linkers
- Solid lipid nanoparticles (SLNP)
- Lipid nanoparticle (LNP) formulations
News & Updates
Nammi Therapeutics has dosed the first patient in a Phase 1 trial of QXL138AM for advanced solid tumors and multiple myeloma.
The company announced a $1M investment commitment by the Myeloma Investment Fund in a $30M Series B financing round.
The company was featured in an interview highlighting recent achievements including the CIRM award and Amgen Golden Ticket.
FDA granted orphan drug designation to QXL138AM for pancreatic cancer treatment.
Received a $3,999,113 grant to complete manufacture and testing for FDA approval for clinical trials.
Awarded the third Amgen Golden Ticket, providing lab space and connections to Amgen's leaders.
Nammi Therapeutics has dosed the first patient in a Phase 1 trial of QXL138AM for advanced solid tumors and multiple myeloma.
The company announced a $1M investment commitment by the Myeloma Investment Fund in a $30M Series B financing round.
The company was featured in an interview highlighting recent achievements including the CIRM award and Amgen Golden Ticket.
FDA granted orphan drug designation to QXL138AM for pancreatic cancer treatment.
Received a $3,999,113 grant to complete manufacture and testing for FDA approval for clinical trials.
Awarded the third Amgen Golden Ticket, providing lab space and connections to Amgen's leaders.